跳至主要内容
临床试验/NL-OMON24910
NL-OMON24910已完成不适用

Prospective evaluation of the predictive value of a circulating tumor cell (CTC) sensitivity profile to Cisplatin chemotherapy in metastatic breast cancer patients

Erasmus MC Cancer Center, Department of Medical Oncology0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100

研究概览

简要总结

de Kruijff et al. Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients. Frontiers in Oncology (2021)

研究设计

研究类型
Interventional

入排标准

入选标准

  • Female patient with metastatic breast cancer who has been pretreated with at least anthracycline and taxane-based chemotherapy in the adjuvant and/or metastatic setting
  • - Measurable disease according to RECIST 1.1, i.e. at least one measurable lesion on CT-scan where the longest diameter in the plane of measurement is a minimum size of 10mm

排除标准

  • - Other anticancer chemotherapy, use of biological response modifiers, or immunotherapy within two weeks prior to treatment start. Hormonal antitumor treatment within one week prior to treatment start.
  • - Hearing loss of at least Common Terminology Criteria for Adverse Events (CTCAE) grade 2

研究者

发起方
Erasmus MC Cancer Center, Department of Medical Oncology

相似试验